We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
26
Revolution Medicines
RVMD
$39.6B
$7.86M 1.34%
80,872
+43,852
+118% +$4.43M
KOD icon
27
Kodiak Sciences
KOD
$2.67B
$7.36M 1.25%
+192,962
New +$4.99M
INCY icon
28
Incyte
INCY
$23.4B
$7.34M 1.25%
+78,029
New +$7.79M
TGTX icon
29
TG Therapeutics
TGTX
$8.4B
$6.87M 1.17%
206,928
+83,645
+68% +$2.49M
EWTX icon
30
CALL
Edgewise Therapeutics
EWTX
$4.28B
$6.69M 1.14%
+212,500
New +$6.13M
CORT icon
31
CALL
Corcept Therapeutics
CORT
$9.72B
$6.39M 1.09%
+158,500
New +$5.93M
BBIO icon
32
BridgeBio Pharma
BBIO
$15.9B
$6.34M 1.08%
85,311
+15,311
+22% +$1.11M
GPCR icon
33
PUT
Structure Therapeutics
GPCR
$3.45B
$6.15M 1.05%
+127,500
New +$8.73M
IMCR icon
34
Immunocore
IMCR
$1.78B
$5.82M 0.99%
193,189
+122,889
+175% +$3.98M
LLY icon
35
Eli Lilly
LLY
$1.05T
$5.52M 0.94%
6,000
+4,000
+200% +$4.06M
ABBV icon
36
AbbVie
ABBV
$450B
$5.23M 0.89%
+24,058
New +$5.34M
RCUS icon
37
Arcus Biosciences
RCUS
$3.44B
$5.14M 0.88%
+238,142
New +$5.14M
CRSP icon
38
CALL
CRISPR Therapeutics
CRSP
$4.71B
$5.06M 0.86%
106,300
-6,400
-6% -$338K
QURE icon
39
PUT
uniQure
QURE
$2.77B
$4.89M 0.83%
299,000
-2,800
-0.9% -$56.7K
CRBP icon
40
Corbus Pharmaceuticals
CRBP
$167M
$4.13M 0.7%
+439,957
New +$3.7M
QURE icon
41
CALL
uniQure
QURE
$2.77B
$4.09M 0.7%
+250,000
New +$5.06M
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$1.25B
$3.58M 0.61%
+244,811
New +$3.91M
ZYME icon
43
Zymeworks
ZYME
$1.78B
$3.56M 0.61%
+142,132
New +$3.36M
REPL icon
44
PUT
Replimune Group
REPL
$859M
$3.52M 0.6%
+459,900
New +$3.52M
GPCR icon
45
Structure Therapeutics
GPCR
$3.45B
$3.48M 0.59%
+72,234
New +$4.94M
CYTK icon
46
CALL
Cytokinetics
CYTK
$10.9B
$3.3M 0.56%
+50,000
New +$3.18M
PCVX icon
47
CALL
Vaxcyte
PCVX
$8.12B
$3.09M 0.53%
+53,100
New +$2.88M
GLUE icon
48
Monte Rosa Therapeutics
GLUE
$2.07B
$3.08M 0.52%
187,307
+125,026
+201% +$2.39M
TENX icon
49
Tenax Therapeutics
TENX
$420M
$2.87M 0.49%
179,738
-63,432
-26% -$858K
BHVN icon
50
CALL
Biohaven
BHVN
$2.32B
$2.68M 0.46%
317,000
+117,000
+59% +$1.28M
1
2
3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.